GlaxoSmithKline ( GlaxoSmithKline )

  • Calling pr ads
  • Calling pr ads


GlaxoSmithKline's picture

GlaxoSmithKline started operations on 1 January 2001 following the merger of GlaxoWellcome plc and SmithKline Beecham plc, but our combined histories go back much further than that. Find out about the many products and mergers that led to the GSK we know today.

GlaxoSmithKline press release, blog etc

12/12/2017 - 11:50 GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US
12/11/2017 - 12:47 GSK presents promising new data for priority BCMA asset from its emerging Oncology pipeline at 59th ASH meeting
12/06/2017 - 17:47 GSK welcomes launch of the UK Governments Life Sciences Sector Deal
12/06/2017 - 16:12 New data supports the safety and efficacy of GSKs Shingrix in preventing shingles in autologous haematopoietic stem cell transplant patients
11/30/2017 - 01:58 ViiV Healthcare announces start of phase III study of long-acting cabotegravir for HIV prevention in women
11/28/2017 - 09:43 GSK submits US regulatory application for single-dose tafenoquine for Plasmodium vivax malaria
11/27/2017 - 10:32 ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine
11/23/2017 - 03:50 GSK submits landmark IMPACT data to US regulatory authority to support expanded label for Trelegy Ellipta
11/21/2017 - 01:23 Juluca (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection
11/16/2017 - 04:40 Trelegy Ellipta once-daily single inhaler triple therapy gains marketing authorisation in Europe for the treatment of COPD
11/13/2017 - 10:52 GSK receives European marketing authorisation for self-injectable formulation of Benlysta for the treatment of systemic lupus erythematosus
11/08/2017 - 10:45 Dr Hal Barron appointed Chief Scientific Officer and President, Research & Development, GSK
11/08/2017 - 10:33 Patrick Vallance, President, R&D, GSK to become UK Government's Chief Scientific Adviser
11/08/2017 - 09:43 First long-term efficacy analysis on the effect of GSKs Benlysta on rate of organ damage progression in SLE versus standard therapy alone
11/06/2017 - 21:13 GSK submits US regulatory application for mepolizumab in eosinophilic chronic obstructive pulmonary disease (COPD)
11/06/2017 - 11:44 New multi-country survey reveals need for improved awareness around long-term impact and appropriate use of corticosteroids in SLE management
11/02/2017 - 03:04 GSKs investigational BCMA antibody-drug conjugate receives Breakthrough Therapy Designation from US FDA for relapsed and refractory multiple myeloma
11/01/2017 - 03:00 GSK study demonstrates superiority of Anoro Ellipta to Stiolto Respimat in improving lung function in chronic obstructive pulmonary disease